Adial Pharmaceuticals, Inc.
|Number of Estimates|
Adial Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which focuses on the treatment of alcohol use disorder. Its lead product is AD04, a selective serotonin-3 antagonist. The company was founded by Bankole A. Johnson in November 2010 and is headquartered in Charlottesville, VA.
Market Cap: 24.7 Million
Primary Exchange: NASDAQ
Shares Outstanding: 13.4 Million
Float: 10.5 Million
Sector: Health Technology
Industry: Pharmaceuticals: Major
Longest drawdown: 1041 trading days
From: 2019-01-15 To: 2020-08-10
|Ex-Date||Payment Date||Record Date||Declared Date||Amount||Flag||Dividend Type||Qualified||Indicated|
|Ex-Date||Declared Date||Record Date||Payment Date||Ratio||To Factor||For Factor|